![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SYP |
Gene summary for SYP |
![]() |
Gene information | Species | Human | Gene symbol | SYP | Gene ID | 6855 |
Gene name | synaptophysin | |
Gene Alias | MRX96 | |
Cytomap | Xp11.23 | |
Gene Type | protein-coding | GO ID | GO:0001505 | UniProtAcc | P08247 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6855 | SYP | HCC1_Meng | Human | Liver | HCC | 9.78e-04 | -1.72e-02 | 0.0246 |
6855 | SYP | S014 | Human | Liver | HCC | 5.00e-11 | 4.36e-01 | 0.2254 |
6855 | SYP | S015 | Human | Liver | HCC | 4.18e-16 | 7.48e-01 | 0.2375 |
6855 | SYP | S016 | Human | Liver | HCC | 2.72e-22 | 7.13e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605021 | Liver | HCC | vesicle organization | 194/7958 | 300/18723 | 5.58e-15 | 3.97e-13 | 194 |
GO:002176222 | Liver | HCC | substantia nigra development | 33/7958 | 44/18723 | 1.21e-05 | 1.38e-04 | 33 |
GO:003090121 | Liver | HCC | midbrain development | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
GO:004885722 | Liver | HCC | neural nucleus development | 38/7958 | 64/18723 | 4.78e-03 | 2.02e-02 | 38 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SYP | SNV | Missense_Mutation | novel | c.305N>T | p.Ser102Leu | p.S102L | P08247 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
SYP | SNV | Missense_Mutation | novel | c.41T>C | p.Val14Ala | p.V14A | P08247 | protein_coding | tolerated(0.18) | probably_damaging(0.978) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SYP | SNV | Missense_Mutation | rs781872198 | c.334N>A | p.Val112Met | p.V112M | P08247 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
SYP | SNV | Missense_Mutation | c.184N>C | p.Glu62Gln | p.E62Q | P08247 | protein_coding | tolerated(0.61) | benign(0.184) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
SYP | SNV | Missense_Mutation | rs782047632 | c.398N>A | p.Arg133Gln | p.R133Q | P08247 | protein_coding | deleterious(0.03) | possibly_damaging(0.838) | TCGA-E2-A15I-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
SYP | SNV | Missense_Mutation | novel | c.470N>T | p.Ser157Leu | p.S157L | P08247 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
SYP | SNV | Missense_Mutation | novel | c.854G>C | p.Gly285Ala | p.G285A | P08247 | protein_coding | tolerated(0.54) | benign(0) | TCGA-AA-3522-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SYP | SNV | Missense_Mutation | rs372570311 | c.59N>A | p.Arg20Gln | p.R20Q | P08247 | protein_coding | tolerated(0.38) | benign(0.005) | TCGA-CM-6678-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
SYP | SNV | Missense_Mutation | novel | c.503N>C | p.Lys168Thr | p.K168T | P08247 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SYP | SNV | Missense_Mutation | novel | c.592N>T | p.Thr198Ser | p.T198S | P08247 | protein_coding | deleterious(0.03) | benign(0.216) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6855 | SYP | TRANSPORTER | DIMETHYL SULFOXIDE | 2512391 | ||
6855 | SYP | TRANSPORTER | MORPHINE | MORPHINE | 10710628 | |
6855 | SYP | TRANSPORTER | 6-HYDROXYDOPAMINE | 15765516 |
Page: 1 |